Last reviewed · How we verify
NCT07273760
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
trial testing Vedolizumab in Ulcerative Colitis (UC) in 150 participants. Completed in 5 October 2025.
30 September 2025
Quick facts
| Lead sponsor | AryoGen Pharmed Co. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 16 July 2023 |
| Primary completion | 30 September 2025 |
| Estimated completion | 5 October 2025 |
| Sites | 12 locations across Iran |
Drugs / interventions tested
- Vedolizumab (vedolizumab) — full drug profile →
Conditions studied
- Ulcerative Colitis (UC) — all drugs for Ulcerative Colitis (UC) →
- Crohn Disease (CD) — all drugs for Crohn Disease (CD) →
- Inflammatory Bowel Disease (IBD) — all drugs for Inflammatory Bowel Disease (IBD) →
Sponsor
AryoGen Pharmed Co. — full company profile →
Who can join
Eligibility, any sex, with Ulcerative Colitis (UC) or Crohn Disease (CD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this observational study is to evaluate Effectiveness and safety of VedAryo® (Vedolizumab) in male or female participants with clinical diagnosis of Inflammatory Bowel Disease. The main questions are aim to answer: 1. Is VedAryo® (Vedolizumab) effective in the treatment of Inflammatory Bowel Disease? 2. Is VedAryo® (Vedolizumab) safe in the treatment of Inflammatory Bowel Disease? In this study, there is no comparison group. Participants received VedAryo® (Vedolizumab)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07273760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vedolizumab
Trials testing the same drug.
- NCT06646016 — EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis · Phase 2 · withdrawn
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT06227910 — A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease · Phase 3 · recruiting
- NCT06443502 — A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pou · Phase 3 · recruiting
- NCT06570772 — Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio · Phase 3 · terminated
Other recruiting trials for Ulcerative Colitis (UC)
Currently open trials in the same condition.
- NCT07335055 — A Study for HSK47388 in Participants With Ulcerative Colitis · Phase 2 · recruiting
- NCT07271069 — Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis · recruiting
- NCT07245394 — Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) · recruiting
- NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
- NCT07350577 — Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants · Phase 1 · recruiting
Other AryoGen Pharmed Co. trials
Trials by the same sponsor.
- NCT06137092 — rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study · Phase 3 · completed
- NCT04789954 — Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors · EARLY_PHASE1 · completed
- NCT03935334 — Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors · Phase 3 · completed
- NCT03293108 — Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bo · Phase 3 · unknown
- NCT03079063 — Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII D · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07273760 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AryoGen Pharmed Co.
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07273760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing